Pegcetacoplan Treatment Meaningfully Improves Quality Of Life And Fatigue In Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From Two Phase 3 Clinical Trials (EBMT 2022) - Apellis Medical Hub

Pegcetacoplan Treatment Meaningfully Improves Quality Of Life And Fatigue In Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From Two Phase 3 Clinical Trials

Share Via Email

Back to Conference Resources

PNH Congress Presentations The European Society for Blood and Marrow Transplantation (EBMT) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.